#1 Clinical Trials Search in Europe

Rbd5044 Sodium

Clinical trials are currently underway to assess the effectiveness and safety of RBD5044 Sodium, a new drug designed to treat mixed dyslipidemia. This condition involves abnormal levels of various lipids in the blood, which can increase the risk of heart disease. The trials aim to determine how well RBD5044 Sodium works in managing lipid levels and its potential as a treatment option for patients with this condition.

Table of Contents

What is RBD5044?

RBD5044 SODIUM is a new medication being studied for the treatment of mixed dyslipidemia. It is classified as a small interfering RNA, which is a type of drug that works at the genetic level to influence how certain proteins are produced in the body[1]. The medication is given as an injection under the skin (subcutaneous injection).

Medical Condition: Mixed Dyslipidemia

Mixed dyslipidemia is a condition where a person has abnormal levels of different types of fats (lipids) in their blood. This typically includes high levels of triglycerides and low-density lipoprotein cholesterol (LDL-C, often called “bad” cholesterol), along with low levels of high-density lipoprotein cholesterol (HDL-C, often called “good” cholesterol)[1]. This condition increases the risk of heart disease and other cardiovascular problems.

How RBD5044 Works

While the exact mechanism is not fully described in the trial information, RBD5044 is designed to improve the balance of lipids in the blood of patients with mixed dyslipidemia. It specifically targets a protein called apolipoprotein-CIII (apoC-III), which plays a role in regulating triglyceride levels[1]. By affecting this protein, RBD5044 aims to reduce triglycerides and improve overall lipid profiles in patients.

Clinical Trial Details

RBD5044 is currently being studied in a Phase 2 clinical trial. Here are some key details about the study:

  • It is a randomized, double-blind, placebo-controlled trial, which means participants are randomly assigned to either receive RBD5044 or a placebo, and neither the participants nor the researchers know who is receiving which treatment[1].
  • The study will test different doses of RBD5044 to determine which is most effective and safe[1].
  • The main goal is to see how well RBD5044 reduces triglyceride levels after 16 weeks of treatment[1].
  • The study will also look at changes in other lipid parameters, including LDL-C, HDL-C, and total cholesterol, among others[1].
  • The trial will last for 48 weeks in total, allowing researchers to assess both short-term and longer-term effects of the medication[1].

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key eligibility factors include:

  • Age between 18 and 80 years[1].
  • Fasting triglyceride levels between 150 mg/dL and 499 mg/dL[1].
  • Certain levels of non-HDL-C or LDL-C[1].
  • Body mass index (BMI) between 18 and 40 kg/m²[1].

There are also several exclusion criteria, such as uncontrolled diseases, recent significant illnesses, and certain laboratory values, which would prevent a person from participating in the trial[1].

Potential Benefits

If successful, RBD5044 could offer several benefits for patients with mixed dyslipidemia:

  • Reduction in triglyceride levels[1].
  • Improvement in overall lipid profile, including potential increases in HDL-C and decreases in LDL-C[1].
  • Potential reduction in cardiovascular risk, although this would need to be confirmed in larger, longer-term studies[1].

Safety and Side Effects

As RBD5044 is still in the testing phase, all potential side effects are not yet known. The clinical trial is designed to carefully monitor for any adverse effects. Some points to note:

  • The study will track the frequency, intensity, and seriousness of any side effects throughout the 48-week trial period[1].
  • Researchers will monitor changes in laboratory parameters, vital signs, physical examinations, and ECG results[1].
  • As with any injectable medication, there may be reactions at the injection site. People with a history of severe intolerance to subcutaneous injections are not eligible for the study[1].

It’s important to remember that RBD5044 is still an experimental treatment. While it shows promise, more research is needed to fully understand its effectiveness and safety profile. Patients with mixed dyslipidemia should continue to work with their healthcare providers to manage their condition using currently approved treatments while research on new options like RBD5044 continues.

Aspect Details
Drug Name RBD5044 Sodium
Drug Type Small interfering RNA
Administration Method Subcutaneous injection
Target Condition Mixed Dyslipidemia
Primary Objective Evaluate efficacy in reducing triglyceride levels
Secondary Objectives Assess safety, tolerability, plasma exposure, and effects on various lipid parameters
Trial Duration 48 weeks
Key Inclusion Criteria Age 18-80, specific triglyceride and cholesterol levels, stable diet and statin therapy
Key Exclusion Criteria Uncontrolled diseases, recent significant illness, excessive alcohol consumption, drug abuse
Primary Endpoint Percent change in triglyceride levels at week 16
Study Design Randomized, double-blind, placebo-controlled, parallel-group, Phase 2 trial

FAQ

  • What is RBD5044 Sodium and how is it administered? RBD5044 Sodium is a small interfering RNA medication being tested for the treatment of mixed dyslipidemia. It is administered through subcutaneous injection, which means it's injected just under the skin.
  • What is the main goal of the clinical trial for RBD5044 Sodium? The main goal of the trial is to evaluate how effective RBD5044 Sodium is in treating patients with mixed dyslipidemia, particularly by measuring changes in triglyceride levels after 16 weeks of treatment.
  • Who can participate in the RBD5044 Sodium clinical trial? Participants must be between 18 and 80 years old, have specific levels of triglycerides and other lipids in their blood, and meet other health criteria. They should not have uncontrolled diseases or recent significant illnesses.
  • How long does the clinical trial for RBD5044 Sodium last? The clinical trial lasts for 48 weeks (about 11 months). During this time, participants will receive the medication or a placebo and undergo various assessments to monitor its effects and safety.
  • What are the potential benefits of RBD5044 Sodium? RBD5044 Sodium is being studied for its potential to lower triglycerides and improve other lipid parameters in people with mixed dyslipidemia. If successful, it could offer a new treatment option for managing this condition and reducing cardiovascular risk.

Ongoing Clinical Trials on Rbd5044 Sodium

  • Study of RBD5044 in Adults with Mixed Dyslipidemia to Evaluate its Safety and Effectiveness

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Poland Sweden

Glossary

  • Mixed Dyslipidemia: A condition characterized by abnormal levels of multiple types of lipids (fats) in the blood, typically involving high triglycerides and low HDL cholesterol.
  • Triglycerides (TG): A type of fat found in your blood that your body uses for energy. High levels can increase your risk of heart disease.
  • LDL-C (Low-Density Lipoprotein Cholesterol): Often called 'bad' cholesterol, high levels of LDL-C can lead to buildup in your arteries, increasing the risk of heart disease.
  • HDL-C (High-Density Lipoprotein Cholesterol): Often referred to as 'good' cholesterol, HDL-C helps remove other forms of cholesterol from your bloodstream.
  • Apolipoprotein C-III (apoC-III): A protein that plays a role in regulating triglyceride levels in the blood.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of fat just beneath the skin.
  • Placebo: A substance with no active medical effects, used as a control in testing new drugs.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-rbd5044-for-patients-with-mixed-dyslipidemia/